Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-29T21:25:47.303Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of the oral vasopressin receptor antagonist tolvaptan on congestive cardiac failure in a child with restrictive cardiomyopathy

Published online by Cambridge University Press:  07 February 2013

Yoko Horibata ,
Tomoaki Murakami  and
Koichiro Niwa
Yoko Horibata*
Affiliation:
Department of Adult Congenital Heart Disease, Chiba Cardiovascular Center, Ichihara, Chiba, Japan
Tomoaki Murakami
Affiliation:
Department of Adult Congenital Heart Disease, Chiba Cardiovascular Center, Ichihara, Chiba, Japan
Koichiro Niwa
Affiliation:
Department of Cardiology, Cardiovascular Center, St. Luke's International Hospital, Tokyo, Japan
*
Correspondence to: Yoko Horibata, Department of Adult Congenital Heart Disease, Chiba Cardiovascular Center, 575 Tsurumai, Ichihara, Chiba 290-0512, Japan. Tel: +81-436-88-3111; Fax: +81-436-88-3032; E-mail: horibata@kumamoto-u.ac.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

Tolvaptan, an oral vasopressin receptor antagonist, was administered to a 6-year-old boy with advanced congestive cardiac failure due to restrictive cardiomyopathy. Slow up-titration of the tolvaptan improved the loop diuretic-resistant congestive cardiac failure without hypernatraemia, deterioration of vital signs, and significant complications. Tolvaptan could be useful and safe for children with severe congestive cardiac failure. It is necessary to accumulate clinical data on tolvaptan administration in children in order to determine the optimal method of administration.

Keywords

Tolvaptanpaediatricscongestive cardiac failurediuretics
Type
Brief Reports
Information
Cardiology in the Young , Volume 24 , Issue 1 , February 2014 , pp. 155 - 157
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Zmily, HD, Daifallah, S, Ghali, JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis 2011; 4: 57–71.Google Scholar
2. Gheorghiade, M, Konstam, MA, Burnett, JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332–1343.Google Scholar
3. Konstam, MA, Gheorghiade, M, Burnett, JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319–1331.Google Scholar
4. Goldsmith, SR, Gheorghiade, M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46: 1785–1791.Google Scholar
5. Eshaghian, S, Horwich, TB, Fonarow, GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759–1764.Google Scholar
6. Udelson, JE, McGrew, FA, Flores, E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151–2159.Google Scholar
7. Gheorghiade, M, Gattis, WA, O'Connor, CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–1971.Google Scholar